Virtual issue on Melanoma
Most recent reviews and articles on melanoma [2010] [2009] [2008] [2007] [2006] [2005]
Melanoma – a look down the road ahead
By Ze’ev Ronai, PhD, Burnham Institute for Medical Research, La Jolla, USA www.ronailab.net
Malignant melanoma is one of the most highly invasive and metastatic tumors. Correspondingly, the primary clinical barriers to effective melanoma treatment are the high propensity for tumors to metastasize and the strong resistance of tumors to available treatments.
A significant advance in understanding melanoma biology was made over recent years when genetic changes along the MAPK signaling pathway (B-Raf and N-Ras mutations) were identified. Identification of these types of mutations in many melanoma tumors has significantly increased our understanding of genetic changes underlying melanoma. Yet, it is critical to note that identical genetic changes do not always underlie different melanoma subtypes. For example, mutations seen in melanomas associated with sun exposure differ from those seen in other subtypes, and some melanoma subtypes exhibit mutations in signaling pathways other than MAPK kinase. For example, c-Kit mutations were found in about 30% of mucosal, acral and other melanomas developing on chronically sun-exposed skin, conditions in which mutations in MAPK pathway components were not seen. Thus, while we have greatly advanced our understanding melanoma as a cancer marked by deregulation of well-defined signaling pathways, it is now clear that changes in multiple pathways exist among melanoma subtypes. Understanding these differences will dictate how selective therapies are developed and applied.
Adding to the complexity is the growing recognition that pathways are re-wired in melanoma. In tumors, MAPK-related pathways intersect with and influence regulatory pathways not thought to be linked in normal cells. Thus, the molecular analysis of changes in melanoma will require extensive dissection of multiple pathways influenced by deregulated genes. For example, further understanding of mechanisms underlying deregulated AKT signaling in melanoma awaits characterization.
Equally important is the growing realization that central to the etiology of melanoma is a small but potent population of melanoma initiating (stem?) cells. This exciting topic is receiving growing attention and should provide important insight into the handful of cells capable of initiating a tumor. Although currently only a few groups are dedicating their efforts to this exciting observation, an emerging theme in cancer research is that melanoma initiating cells may be as complex as melanoma tumors are.
Understanding tumor microenvironment has been and will remain critical to our understanding of melanoma progression, given that a hallmark of melanoma is its metastatic potential. The development of mouse models and better technologies to study tumor microenvironment (from 3D cultures to lymph-angiogenesis) provides tools necessary for identifying mechanisms underlying melanoma metastasis and finding selective means to halt it, as well as models to assess possible therapeutic approaches.
The growing number of selective markers used to detect melanoma tumors and follow metastatic lesions, combined with improved imaging technologies, generate optimism that we will devise better diagnostics and more efficient treatment strategies.
Together with these exciting developments in basic research come extensive efforts to develop drugs specifically targeting a given signaling pathway. Some newly developed drugs targeting B-Raf mutations are presently in clinical trials; other drugs, such as those available to treat melanomas harboring c-Kit mutations, are being also evaluated. With high expectations for the success of selective treatment regimens, we also recognize that targeting a single regulatory component may not be sufficient for melanoma therapy. Thus we must identify and better characterize other targets associated with deregulated pathways in melanoma in order to treat this tumor type efficiently and selectively.
Recent Articles Published on Melanoma
2010
Roles of Endothelin Signaling in Melanocyte Development and Melanoma
Amy Saldana-Caboverde, Lidia Kos
Multicentre study on standardisation of melanoma cell culture – an initiative of the German Melanoma Research Network
Eberle J, Spangler B, Becker J, Heinemann SH, Klein CA, Kunz M, Kuphal S, Langer P, Mauch C, Meierjohann S, Paschen A, Schadendorf D, Schartl M, Schittek B, Schoenherr R, Tueting T, Zigrino P, Bosserhoff AK
PLX4032, a Selective BRAFV600E Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAFWT Melanoma Cells
Ruth Halaban, Wengeng Zhang, Antonella Bacchiocchi, Elaine Cheng, Fabio Parisi, Stephan Ariyan, Michael Krauthammer, James P. McCusker, Yuval Kluger, Mario Sznol
Mutation spectrum of the first melanoma genome points finger firmly at ultraviolet light as the primary carcinogen
Nicholas K. Hayward
Roles of Endothelin Signaling in Melanocyte Development and Melanoma
Amy Saldana-Caboverde, Lidia Kos
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure
Despina Handolias, Renato Salemi, William Murray, Angela Tan, Wendy Liu, Amaya Viros, Alexander Dobrovic, John Kelly, Grant A McArthur
Cell cycle inhibitor p21/ WAF1/ CIP1 as a cofactor of MITF expression in melanoma cells
Blanka Šestáková, Lubica Ondrušová, Jiri Vachtenheim
αB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells
Rong Hu, Andrew E. Aplin
PAX3 and SOX10 activate MET receptor expression in melanoma
Joseph B. Mascarenhas, Erica L. Littlejohn, Rebecca J. Wolsky, Kacey P. Young, Maria Nelson, Ravi Salgia, Deborah Lang
Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma
David Baltimore, Owen N. Witte, Lili Yang, James Economou, Antoni Ribas
Functional alterations in protein kinase C beta II expression in melanoma
John P. Voris, Leonid A. Sitailo, Heidi R. Rahn, Ann Defnet, Aaron T. Gerds, Robert Sprague, Vipin Yadav, I. Caroline Le Poole, Mitchell F. Denning
Fifteen-year quest for microphthalmia-associated transcription factor target genes
Yann Cheli, Mickael Ohanna, Robert Ballotti, Corine Bertolotto
AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1)
Seung-Shick Shin, Brian A. Wall, James S. Goydos, Suzie Chen
Keratinocytes in culture accumulate phagocytosed melanosomes in the perinuclear area
Hideya Ando, Yoko Niki, Masaki Yoshida, Masaaki Ito, Kaoru Akiyama, Jin-Hwa Kim, Tae-Jin Yoon, Jeung-Hoon Lee, Mary S. Matsui, Masamitsu Ichihashi
Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma
David Baltimore, Owen N. Witte, Lili Yang, James Economou, Antoni Ribas
Melanoma from bench to bedside: meeting report from the 6th international melanoma congress
D. E. Fisher, R. Barnhill, F. S. Hodi, M. Herlyn, G. Merlino, E. Medrano, B. Bastian, T. M. Landi, J. Sosman
UVA tanning is involved in the increased incidence of skin cancers in fair-skinned young women
Sergio G. Coelho, Vincent J. Hearing
2009
Functional Alterations in Protein Kinase C BetaII Expression in Melanoma
John P. Voris, Leonid A. Sitailo, Heidi R. Rahn, Ann Defnet, Aaron T. Gerds, Robert Sprague, Vipin Yadav, I. Caroline Le Poole, Mitchell F. Denning
Inducible expression of V600EBraf using tyrosinase-driven Cre recombinase results in embryonic lethality
Nathalie Dhomen, Silvy Da Rocha Dias, Robert Hayward, Lesley Ogilvie, Douglas Hedley, Veronique Delmas, Afshan McCarthy, Deborah Henderson, Caroline J Springer, Catrin Pritchard, Lionel Larue, Richard Marais
The PGF2a receptor FP is lost in nevi and melanoma
Alex Fricke, Lindy McClelland, Glynis Scott
High Molecular Weight−Melanoma-Associated Antigen as a Biomarker of Desmoplastic Melanoma
Yasufumi Goto, Takaaki Arigami, Rajmohan Murali, Richard A. Scolyer, Atsushi Tanemura, Minoru Takata, Roderick R. Turner, Linhda Nguyen, Tung Nguyen, Donald L. Morton, Soldano Ferone, Dave S.B. Hoon
15-year quest in search for MITF target genes
Yann Cheli, Mickael Ohanna, Robert Ballotti, Corine Bertolotto
ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma
Aline Primot, Ariane Mogha, Sébastien Corre, Karen Roberts, Julien Debbache, Henri Adamski, Brigitte Dreno, Amir Khammari, Thierry Lesimple, Agnes Mereau, Colin R Goding, Marie-Dominique Galibert
Dormancy of metastatic melanoma
Liliana Ossowski, Julio A. Aguirre-Ghiso
TYRO3-mediated regulation of MITF: a novel target in melanoma?
Udo Rudloff, Yardena Samuels
Enhancement of DNA repair using topical T4 endonuclease V does not inhibit melanoma formation in Cdk4R24C/R24C/Tyr-NrasQ61K mice following neonatal UVR
Elke Hacker, H. Konrad Muller, Nicholas Hayward, Paul Fahey, Graeme Walker
Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma
Minoru Takata, Hiroshi Murata, Toshiaki Saida
Unique transforming properties of Notch1 in human melanocytes
Barbara Bedogni, Marianne Broome Powell
Double stranded RNA tricks melanoma cells into committing suicide
Romina S. Goldszmid, Uzma A. Hasan, Giorgio Trinchieri
Mutated ERBB4: a novel drug target in metastatic melanoma?
Kari Kurppa, Klaus Elenius
Recent advances and hurdles in melanoma immunotherapy
Camilla Jandus, Daniel Speiser, Pedro Romero
Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt
Michael P. O'Connell, Ashani T. Weeraratna
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma
Kevin G. Chen, Julio C. Valencia, Jean-Pierre Gillet, Vincent J. Hearing, Michael M. Gottesman
SKI knockdown inhibits human melanoma tumor growth in vivo
Dahu Chen, Qiushi Lin, Neil Box, Dennis Roop, Shunsuke Ishii, Koichi Matsuzaki, Tao Fan, Thomas J. Hornyak, Jon A Reed, Ed Stavnezer, Nikolai A. Timchenko, Estela E. Medrano
NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation
Kristina Buac, Mai Xu, Julie Cronin, Ashani T. Weeraratna, Stephen M. Hewitt, William J. Pavan
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma
Leisl M Packer, Philip East, Jorge S Reis-Filho, Richard Marais
Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis
Meera Shah, John L. Stebbins, Antimone Dewing, Jianfei Qi, Maurizio Pellecchia, Ze'ev A. Ronai
a-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes
Xiuzu Song, Nicole Mosby, Jennifer Yang, Aie Xu, Zalfa Abdel-Malek, Ana Luisa Kadekaro
Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease
Julie Charles, Isabelle Templier, Dominique Leroux, Dimitri Salameire, Caroline Robert, Sylvie Lantuejoul, Marie-Therese Leccia
Melanocyte and RPE-specific expression in transgenic mice by mouse MART-1/Melan-A/mlana regulatory sequences
Iraz T. Aydin, Friedrich Beermann
F-box proteins FBXO31 and FBX4 in regulation of cyclin D1 degradation upon DNA damage
Lijun Jia, Yi Sun
Secrets to developing Wnt-age melanoma revealed
Lionel Larue, Véronique Delmas
miR(acle)s – new players in the regulation of known suspects
Daniel W. Müller, Anja K. Bosserhoff
Genome-wide associations studies for melanoma and nevi
Iwei Yeh, Boris C. Bastian
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
Keith T. Flaherty, Keiran S. M. Smalley
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008
Sanjiv S. Agarwala, Jurgen C. Becker, Alexander M. Eggermont, Keith T. Flaherty, Claus Garbe, Alisa M. Goldstein, Allan Halpern, Mohammed Kashani-Sabet, Axel Hauschild, John M. Kirkwood, Sancy Leachman, Paul Lorigan, Martin McMahon, Jane Messina, Antoni Ribas, Wolfram E. Samlowski, Dirk Schadendorf, Vernon K. Sondak
The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate
Luís Sánchez-del-Campo, María F. Montenegro, Juan Cabezas-Herrera, José Neptuno Rodríguez-López
Noriko Saito, Jun-ichi Hamada, Hiroshi Furukawa, Arata Tsutsumida, Akihiko Oyama, Emi Funayama, Akira Saito, Tsutomu Tsuji, Mitsuhiro Tada, Tetsuya Moriuchi, Yuhei Yamamoto
RG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation
Kristina Buac, Mai Xu, Julie Cronin, Ashani T. Weeraratna, Stephen M. Hewitt, William J. Pavan
Alpha-MSH Activates Immediate Defense Responses to UV-Induced Oxidative Stress in Human Melanocytes
Xiuzu Song, Nicole Mosby, Jennifer Yang, Aie Xu, Zalfa Abdel-Malek, Ana Luisa Kadekaro
Preclinical & clinical development of targeted therapy in melanoma: attention to schedule
Keith T. Flaherty, Keiran S. M. Smalley
SKI knockdown inhibits human melanoma tumor growth in vivo
Dahu Chen, Qiushi Lin, Neil Box, Dennis Roop, Shunsuke Ishii, Koichi Matsuzaki, Tao Fang, Thomas J. Hornyak, Jon A Reed, Ed Stavnezer, Nikolai A. Timchenko, Estela E. Medrano
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008
Sanjiv S. Agarwala, Jurgen C. Becker, Alexander M. Eggermont, Keith T. Flaherty, Claus Garbe, Alisa M. Goldstein, Allan Halpern, Mohammed Kashani-Sabet, Axel Hauschild, John M. Kirkwood, Sancy Leachman, Paul Lorigan, Martin McMahon, Jane Messina, Antoni Ribas, Wolfram E. Samlowski, Dirk Schadendorf, Vernon K. Sondak
-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes
Zalfa A. Abdel-Malek, Andrew Ruwe, Renny Kavanagh-Starner, Ana Luisa Kadekaro, Viki Swope, Carrie Haskell-Luevano, Leonid Koikov, James J. Knittel
Secrets to developing Wnt-age melanoma revealed
Lionel Larue, Véronique Delmas
Laminin-421 produced by lymphatic endothelial cells induces chemotaxis for human melanoma cells
Noriko Saito, Jun-ichi Hamada, Hiroshi Furukawa, Arata Tsutsumida, Akihiko Oyama, Emi Funayama, Akira Saito, Tsutomu Tsuji, Mitsuhiro Tada, Tetsuya Moriuchi, Yuhei Yamamoto
The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate
Luís Sánchez-del-Campo, María F. Montenegro, Juan Cabezas-Herrera, José Neptuno Rodríguez-López
MITF pathway mutations in melanoma
Satoru Yokoyama, Nunciada Salma, David E. Fisher
Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report
Vernon K. Sondak, Keiran Smalley
Use of liposomes as drug delivery vehicles for treatment of melanoma
Melissa A. Tran, Rebecca J. Watts, Gavin P. Robertson
The PTEN–AKT3 signaling cascade as a therapeutic target in melanoma
SubbaRao V. Madhunapantula, Gavin P. Robertson
Frequent mutations in the MITF pathway in melanoma
Julia C. Cronin, John Wunderlich, Stacie K. Loftus, Todd D. Prickett, Xiaomu Wei, Katie Ridd, Swapna Vemula, Allison S. Burrell, Neena S. Agrawal, Jimmy C. Lin, Carolyn E. Banister, Phillip Buckhaults, Steven A. Rosenberg, Boris C. Bastian, William J. Pavan, Yardena Samuels
Id2 suppression of p15 counters TGF-b-mediated growth inhibition of melanoma cells
Natalie C. Schlegel, Ossia M. Eichhoff, Silvio Hemmi, Sabine Werner, Reinhard Dummer, Keith S. Hoek
Met amplification and tumor progression in Cdkn2a-deficient melanocytes
Matthew W. VanBrocklin, James P. Robinson, Todd Whitwam, Adam R. Guilbeault, Julie Koeman, Pamela J. Swiatek, George F. Vande Woude, Joseph D. Khoury, Sheri L. Holmen
Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome
David A. Solomon, Jung-Sik Kim, Xiaohong R. Yang, Margaret A. Tucker, Alisa M. Goldstein, Yardena Samuels, Todd Waldman
Building the perfect beast: complex mouse models teach surprisingly simple melanoma lessons
Glenn Merlino
Wild-type versus mutant MMP-8 in melanoma: 'When you come to a fork in the road, take it'*
Jessica S. Blackburn, Constance E. Brinckerhoff
Inflammation and melanoma metastasis
Vladislava O. Melnikova, Menashe Bar-Eli
Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study
Chi-Ping Day, John Carter, Carrie Bonomi, Dominic Esposito, Bruce Crise, Betty Ortiz-Conde, Melinda Hollingshead, Glenn Merlino
H-Cadherin expression reduces invasion of malignant melanoma
Silke Kuphal, Adam C. Martyn, Julie Pedley, Lisa M. Crowther, Vanessa F. Bonazzi, Peter G. Parsons, Anja K. Bosserhoff, Nicholas K. Hayward, Glen M. Boyle
Dual loss of Rb1 and Trp53 in melanocytes perturbs melanocyte homeostasis and genetic stability in vitro but does not cause melanoma or pigmentation defects in vivo
Ian D. Tonks, Arne Mould, Victor Nurcombe, Simon M. Cool, Graeme J. Walker, Elke Hacker, Patricia Keith, Wayne A. Schroder, Andrew Cotterill, Nicholas K. Hayward, Graham F. Kay
Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study
Chi-Ping Day, John Carter, Carrie Bonomi, Dominic Esposito, Bruce Crise, Betty Ortiz-Conde, Melinda Hollingshead, Glenn Merlino
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma
Supriya Gaitonde, Surya K De, Marianna Tcherpakov, Antimone Dewing, Hongbin Yuan, Megan Riel-Mehan, Stan Krajewski, Gavin Robertson, Maurizio Pellecchia, Ze'ev Ronai
Maximizing tumor cell invasion
Pat P. Ongusaha, Sam W. Lee
How TGF- and PAX3 regulate suntanning
Mary R. Loeken
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Veronica Höiom, Rainer Tuominen, Max Käller, Diana Lindén, Afshin Ahmadian, Eva Månsson-Brahme, Suzanne Egyhazi, Klas Sjöberg, Joakim Lundeberg, Johan Hansson
Mouse pigmentation mutants help identify a uveal melanoma oncogene
Nicholas K. Hayward
Cracking the system: melanoma complexity demands new therapeutic approaches
Adina Vultur, Meenhard Herlyn
Stepping on the GAS: a brake pedal for melanoma metastasis?
Marika Linja, Levi A. Garraway
Epigenetic marks in melanoma
Hunter W. Richards, Estela E. Medrano
Dendritic cells in the skin – potential use for melanoma treatment
Sanaa El Marsafy, Martine Bagot, Armand Bensussan, Alain Mauviel
Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation
Yeriel Estrada, Jianli Dong, Liliana Ossowski
Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface
Yannève Rolland, Michel Demeule, Laurence Fenart, Richard Béliveau
Wild type and melanoma-associated mutant p16INK4a proteins do not oligomerize in vivo
Heather McKenzie, Therese M. Becker, Lyndee L. Scurr, Richard F. Kefford, Helen Rizos
2008
Effectively targeting BRAF in melanoma: a formidable challenge
Leslie A Fecher, Ravi Amaravadi, Lynn M. Schuchter
All for one, one for all: alternative promoters and Mitf
Eiríkur Steingrímsson
G-protein-coupled receptors and melanoma
Hwa Jin Lee, Brian Wall, Suzie Chen
JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis
Vasileia-Ismini Alexaki, Delphine Javelaud, Alain Mauviel
A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model
Karen ME Dierickx, Renato Morandini, Thi Hien Nguyen, François Salès, Jean-Michel Kauffmann, Ghanem E Ghanem
The antidepressant sertraline downregulates Akt and has activity against melanoma cells
Kalpana K. Reddy, Benjamin Lefkove, Jack L. Arbiser et al.
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Satoru Yokoyama, Erez Feige, Laura L. Poling, Carmit Levy, Hans R. Widlund, Mehdi Khaled, Andrew L. Kung, David E. Fisher
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky, Juergen Bauer, Boris C. Bastian
SKI is critical for repressing the growth inhibitory function of TGF-ß in human melanoma
Jon A. Reed, D. Chen, Q. Lin, E. E. Medrano
How to make a melanoma: what do we know of the primary clonal events?
Dorothy C. Bennett
Pages 27-38
February 2008
Cancer stem cells and human malignant melanoma
Tobias Schatton and Markus H Frank
Pages 39-55
February 2008
2007
The many faces of Notch signaling in skin-derived cells
Chelsea C. Pinnix and Meenhard Herlyn
Pages 458-465
December 2007
DNA microarray analyses of melanoma gene expression: a decade in the mines
Keith S. Hoek
Pages 466-484
December 2007
Cutaneous melanoma in genetically modified animals
Lionel Larue and Friedrich Beermann
Pages 485-497
December 2007
ATF2 on the double - activating transcription factor and DNA damage response protein
Anindita Bhoumik, Pablo Lopez-Bergami and Ze'ev Ronai
Pages 498-506
December 2007
Melanoma senescence: HDAC1 in focus
Colin R. Goding
Pages 336-338
October 2007
Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis
Hans R. Widlund, David E. Fisher
Pages 339-340
October 2007
The HOG-GLI face of melanoma
Menashe Bar-Eli
Pages 341-342
October 2007
Detection of melanoma cells in sentinel lymph nodes by PCR is not yet ready for prime time
Paul B. Chapman
Pages 343-344
October 2007
Wnt5a and PKC, a deadly partnership involved in melanoma invasion
Estela E. Medrano
pages 258-259
August 2007
Melanoma invasion – current knowledge and future directions
Cedric Gaggioli and Erik Sahai
June 2007
Confirmation of a BRAF mutation-associated gene expression signature in melanoma
Peter Johansson, Sandra Pavey and Nicholas Hayward
June 2007
Molecular markers of circulating melanoma cells
Sandra Medic, Robert L. Pearce, Peter J. Heenan and Mel Ziman
pages 80-91
April 2007
Epigenetic events in malignant melanoma
Tanja Rothhammer and Anja-Katrin Bosserhoff
pages 92-111
April 2007
Loss of maspin expression contributes to a more invasive potential in malignant melanoma
Alexandra E. Denk, Marcus Bettstetter, Peter J. Wild, Keith Hoek, Frauke Bataille, Wolfgang Dietmaier and Anja K. Bosserhoff
pages 112-119
April 2007
2006
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8
Vladislava O. Melnikova, Menashe Bar-Eli
October 2006
Pocket protein function in melanocyte homeostasis and neoplasia
Ian D. Tonks, Nicholas K. Hayward, Graham F. Kay
August 2006
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature
Keith S. Hoek, Natalie C. Schlegel, Patricia Brafford, Antje Sucker, Selma Ugurel, Rajiv Kumar, Barbara L. Weber, Katherine L. Nathanson, David J. Phillips, Meenhard Herlyn, Dirk Schadendorf, Reinhard Dummer
August 2006
NF-κB activation in melanoma
Yukiko Ueda, Ann Richmond
April 2006
Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi
Katarzyna Niedojad?o, Karolina ?abeodzka, Ewelina ?ada, Agnieszka Milewska, Barbara W. Chwirot
Katarzyna Niedojadlo, Karolina Labedzka, Ewelina Lada, Agnieszka Milewska, Barbara W. Chwirot
February 2006
Glutamate receptors on human melanocytes regulate the expression of MiTF
M. J. Hoogduijn, I. S. Hitchcock, N. P. M. Smit, J. M. Gillbro, K. U. Schallreuter, P. G. Genever
February 2006
2005
Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression
Anja-Katrin Bosserhoff
December 2005
Adhesion, migration and communication in melanocytes and melanoma
Nikolas K. Haass, Keiran S. M. Smalley, Ling Li, Meenhard Herlyn
June 2005
Histone deacetylase inhibitors and malignant melanoma
Glen M. Boyle, Adam C. Martyn, Peter G. Parsons
June 2005
Original articles
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis
Karita Peltonen, Taija M. Kiviharju, Päivi M. Järvinen, Runar Ra, Marikki Laiho
June 2005
Inhibition of melanoma inhibitory activity (MIA) expression in melanoma cells leads to molecular and phenotypic changes
Jutta Tatzel, Ina Poser, Josef Schroeder, Anja K Bosserhoff
April 2005
Principal expression of two mRNA isoforms (ABCB 5 and ABCB 5 ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes
Kevin G. Chen, Gergely Szakács, Jean-Philippe Annereau, Francois Rouzaud, Xing-Jie Liang, Julio C. Valencia, Chandrasekharam N. Nagineni, John J. Hooks, Vincent J. Hearing, Michael M. Gottesman
April 2005
Decreased expression of Apaf-1 with progression of melanoma
Rita Mustika, Arief Budiyanto, Chikako Nishigori, Masamitsu Ichihashi, Masato Ueda
February 2005
